Clinical Profile of Patients with Disseminated Tuberculosis (DTB) in Human Immune Deficiency Virus (HIV) Infection

Rajneesh Thakur¹, Mohammed Schezan Iqbal²*, Farah Schezan³

INTRODUCTION

Tuberculosis (TB) poses a significant threat to global health even today, causing the second highest mortality rates from an infectious disease worldwide, after Human Immunodeficiency Virus/Acquired Immune-Deficiency Syndrome (HIV/AIDS). TB and HIV are overlapping epidemics and continue to be a major public health challenge. The World Health Organization (WHO) Global Status Report 2016, reports 10.4 million new cases of TB in 2015 of whom 11% were HIV-infected.¹ This is an increase in the number of new TB cases from 9.2 million seen in 2014.

As HIV infection progresses, CD₄⁺ lymphocytes decline in number and function, making the immune system less able to prevent the growth and local cline in number and function, making the immune system less able to prevent the growth and local

© 2019 Pmcog.Net. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

ABSTRACT

Background: We evaluated the clinical profile of HIV positive patients freshly diagnosed with Disseminated Tuberculosis (DTB) and assessed their response to Anti-tuberculosis treatment (ATT).

Aim: To describe various clinical, radiological and pathological parameters encountered in patients of Disseminated Tuberculosis having an HIV co-infection and assessing the response to standard ATT.

Settings and Design: This study is a descriptive study.

Materials and Methods: We conducted a study on 54 patients of disseminated TB with HIV coinfection who were already on Anti-retroviral therapy. Assessment was focused on mode of diagnosis and distribution of organ involvement. Four months of HRZE and two months of HRE were prescribed as the standard ATT.

Effect of this treatment was observed on change in weight, CD₄⁺ counts and HIV RNA viral loads.

Statistical analysis used: Wilcoxon Sign Rank Test for assessing response to ATT.

Results: This study included 54 patients. The lymphatic system was the most commonly involved organ system (64.81%) and other organs involved were the liver (55.56%), the lungs (46.3%), the pleurae (12.96%), the meninges (5.54%) and the bone marrow (3.71%). Median weight at baseline was 53 kg (IQR, 49-58) and after six months of standard ATT was 62 kg (IQR, 58-67) (p<0.001). Median CD₄⁺ count at baseline was 107.5 cells /mm³ (IQR, 51.5-150.75) and after six months of standard ATT was 246 cells /mm³ (IQR, 184-335.75) (p<0.001). Median HIV RNA viral load at baseline was 2,83,575 copies/mL (IQR, 1,78,376.25 - 3,83,370) and after six months of standard ATT was 19,916.5 copies/mL (14,376.25 - 28,622.5) (p<0.001).

Conclusion: DTB in HIV positive patients has a variety of clinical manifestations which should be incorporated in the clinical decision making and change in weight, CD₄⁺ count and HIV RNA viral load is a reliable indicator of therapeutic response in such cases.

Key words: Disseminated TB, HIV, Clinical Profile, ATT, Plasma HIV RNA viral load.

Key Messages: Anti-Tubercular Therapy (ATT) is instrumental in improving clinical and serological parameters in patients of Disseminated TB having an HIV co-infection.

MATERIALS AND METHODS

The present study was conducted over a nine-month period from 1st January 2018 to 30th September 2018.

in a tertiary care hospital of western India. Ethical clearance was obtained from the Institutional Ethics Committee.

**Case Definitions**: Cases have been defined based on definitions provided in WHO- Definitions and reporting framework for tuberculosis - 2013 Revision.

**Presumptive TB** refers to a patient who presents with symptoms or signs suggestive of TB (previously known as a TB suspect).

**A bacteriologically confirmed TB** case is one from whom a biological specimen is positive by smear microscopy, culture or WRD (such as expert MTB/RIF).

**A clinically diagnosed TB** case is one who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with active TB by a clinician or other medical practitioner who has decided to give the patient a full course of TB treatment.

Bacteriologically confirmed or clinically diagnosed cases of TB are further classified as:

**Classification based on anatomical site of disease**

**Pulmonary Tuberculosis (PTB)** refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree.

**Military TB** is classified as PTB because there are lesions in the lungs.

**Disseminated Tuberculosis** is a disease process involving two or more non-contiguous organs or involvement of bone or blood due to widespread blood borne dissemination of TB bacilli.

**Extrapulmonary Tuberculosis (EPTB)** refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges.

**Classification based on history of previous TB treatment**

**New patients** have never been treated for TB or have taken anti-TB drugs for less than 1 month.

**Previously treated patients** have received 1 month or more of anti-TB drugs in the past.

**Classification based on HIV status**

**HIV-positive TB patient** refers to any bacteriologically confirmed or clinically diagnosed case of TB who has a positive result from HIV testing conducted at the time of TB diagnosis or other documented evidence of enrolment in HIV care, such as enrolment in the pre-ART (Anti-retroviral therapy) register or in the ART register once ART has been started.

**HIV-negative TB patient** refers to any bacteriologically confirmed or clinically diagnosed case of TB who has a negative result from HIV testing conducted at the time of TB diagnosis. Any HIV-negative TB patient subsequently found to be HIV-positive should be reclassified accordingly.

**HIV status unknown TB** patient refers to any bacteriologically confirmed or clinically diagnosed case of TB who has no result of HIV testing and no other documented evidence of enrolment in HIV care.

**Exclusion criteria**

i) All patients who were known to be HIV positive and already diagnosed cases of TB (Pulmonary, extrapulmonary, disseminated) and already on ATT.

ii) All patients who could not be followed up either due to long distance or were of a doubtful compliance, based on defaults in anti-retroviral therapy.

All patients who satisfied the above criteria were counselled and a written informed consent was obtained before enlisting them in the study. All patients were assessed clinically for any signs and symptoms. Baseline parameters and baseline CD4+ counts and HIV RNA viral loads were noted. All patients were already on an existing supervised, standard Anti Retro Viral Therapy (ART) regimen (Tenofovir + Lamivudine + Efavirenz) which is available as a fixed dose combination in one tablet. All patients were prescribed a standard Anti-Tubercular Therapy (ATT) of two months HRZE and four months of HRE (Daily regime). Response was assessed at the end of study for any changes in each patient based on clinical grounds in terms of remission of symptoms and increase in weight, immunological status using CD4+ counts, any changes in the HIV viral loads and during the study for any adverse drug reactions to the ATT regimen.

**Statistical analysis**

The Data was recorded on a predesigned data sheet and all entries were double checked for any possible feeding error. Statistical analysis was performed using SPSS very 21 using appropriate statistical tests. A confidence interval of 95% and p value of less than 0.05 were considered to be statistically significant.

**RESULTS**

During the study period, a total of 54 patients with disseminated TB and HIV co-infection were included. The demographic profile of the study population is represented in Table 1.

The median age at presentation in HIV patients was 36 years (IQR, 31.25 - 40.75) with the maximum number in the third decade. The median BMI of the study population before institution of Anti-Tubercular Therapy (ATT) was 19.20 kg/m² (IQR, 16.79 - 20.08). The median CD4+ count of the study sample before start of ATT was found to be 107.5 cells/μl (IQR, 51.5 - 150.75).

The median time interval between diagnosis of HIV infection and TB diagnosis was 37 days (IQR, 16-113).

Of the 54 patients, 2 were found to be AFB positive on sputum examination, 14 yielded positive results for *Mycobacterium tuberculosis* on tissue examination and 50 had significant changes on radiological evaluation, including CT scan and ultrasound. This has been demonstrated in Table 2.

In our study, we found that involvement of the lymphatic system was the commonest, with 35 out of 54 patients (64.81%) being diagnosed to have DTB of the lymphatic system alone or in conjunction with other organ systems. The other commonly involved organ systems included the liver (55.56%), the lungs (46.3%), the pleurae (12.96%), the meninges (5.54%) and the bone marrow (3.71%). These results are depicted in Figure 1.

Weight change after standard six months of ATT was measured and Wilcoxon Sign rank test was applied for significance. There was a statistically significant weight gain after completion of ATT in all age groups (p value <0.001). These have been summarized in Table 3 and Figure 2.

The immunological profile of the sample was assessed by examining the patients’ CD4+ counts at the time of diagnosis and after completion of ATT. The median values of the CD4+ profile have been outlined in
Thakur, et al.: Clinical Profile of Disseminated TB in HIV Patients


Table 4 and Figure 3, showing difference in median CD₄⁺ counts of the sample before and after completion of ATT. There was a statistically significant difference in these values which was assessed by Wilcoxon Sign Rank test.

The HIV RNA viral load of the study population was assessed by examining the patients' HIV RNA viral loads at the time of diagnosis and after completion of ATT. The median values of the HIV viral loads (copies/mL) have been outlined in Table 5 and Figure 4 shows the difference in the median HIV viral load of the study sample before and after completion of ATT. There was a statistically significant difference between the HIV RNA viral loads before and after ATT, which was calculated using the Wilcoxon Sign Rank test (p value < 0.001).

We also studied the adverse events related to ATT and found out that only two patients of our study sample (3.7%) developed adverse reactions to ATT. The diagnosis of hepatotoxicity in our study was based on exclusion of other possible causes, the temporal profile of liver injury and response to temporary cessation of therapy. Similarly, a diagnosis of neuropathy was based after excluding other possible etiological factors. One patient developed transient hepatitis with elevated liver enzymes (SGOT, SGPT) with no clinical jaundice, which subsided after temporary cessation of therapy. One patient developed progressive peripheral neuropathy, which was attributed to Isoniazid in the ATT regimen and the patient was started on Tab Pyridoxine 100 mg per day and his symptoms at the end of our study showed marked improvement.

**DISCUSSION**

In this study, the median age at presentation in HIV patients was 37 years with the maximum number in the third decade. Maheshwari et al.⁴ have recorded the highest incidence of HIV patients in the third decade. Various other Indian and African studies have also shown similar results.⁶,⁷

---

**Table 1: Demographic profile of the study population (n=54) *.**

<table>
<thead>
<tr>
<th>Age Group (Years)</th>
<th>No (n)</th>
<th>Weight at baseline (kg)</th>
<th>Height at baseline (cm)</th>
<th>BMI before at baseline (kg/m²)</th>
<th>CD₄⁺ count at baseline (cells/mm³)</th>
<th>HIV RNA viral load at baseline (copies/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-34</td>
<td>25</td>
<td>55 (49-58)</td>
<td>172 (168-174)</td>
<td>19.16 (16.49-20.09)</td>
<td>94 (56-130)</td>
<td>3,30,541 (1,89,924-5,02,178)</td>
</tr>
<tr>
<td>35-44</td>
<td>21</td>
<td>55 (51-59)</td>
<td>170 (165-174)</td>
<td>18.96 (17.69-21.56)</td>
<td>122 (91-157)</td>
<td>2,25,316 (1,41,824-3,00,105)</td>
</tr>
<tr>
<td>&gt;45</td>
<td>8</td>
<td>47 (43-53)</td>
<td>165 (151-167)</td>
<td>19.43 (15.67-19.77)</td>
<td>115 (50-173)</td>
<td>3,11,526.5 (2,38,689.25-3,58,537)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>54</td>
<td>53 (49-58)</td>
<td>170 (165-174)</td>
<td>19.20 (16.79-20.08)</td>
<td>107.5 (51.5-150.75)</td>
<td>2,83,575 (1,78,376.25-3,83,370)</td>
</tr>
</tbody>
</table>

*All values are given as median (Interquartile range).

**Table 2: Clinical presentation of DTB in HIV seropositive patients (n=54) *.

<table>
<thead>
<tr>
<th>Age</th>
<th>No. (n=54)</th>
<th>Clinical features</th>
<th>Imaging</th>
<th>AFB positivity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever</td>
<td>CE-CT Chest and Abdomen</td>
<td>Sputum</td>
</tr>
<tr>
<td>25-34</td>
<td>25</td>
<td>21 (84)</td>
<td>13 (52)</td>
<td>11 (44)</td>
</tr>
<tr>
<td>35-44</td>
<td>21</td>
<td>14 (66.7)</td>
<td>11 (52.4)</td>
<td>9 (42.8)</td>
</tr>
<tr>
<td>&gt;45</td>
<td>8</td>
<td>7 (87.5)</td>
<td>4 (50)</td>
<td>4 (50)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>54</td>
<td>42 (77.7)</td>
<td>28 (51.8)</td>
<td>24 (44.5)</td>
</tr>
</tbody>
</table>

*Values are given as No. (%).

**Table 3: Weight change after ATT (n=54) *.

<table>
<thead>
<tr>
<th>Age</th>
<th>No. (n=54)</th>
<th>Weight change</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Weight before ATT (kg)</td>
<td>Weight after ATT (kg)</td>
</tr>
<tr>
<td>25-34</td>
<td>25</td>
<td>55 (49-58)</td>
<td>63 (60-70)</td>
</tr>
<tr>
<td>35-44</td>
<td>21</td>
<td>55 (51-59)</td>
<td>65 (58-66)</td>
</tr>
<tr>
<td>&gt;45</td>
<td>8</td>
<td>47 (43-53)</td>
<td>55.5 (46.75-62)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>54</td>
<td>53 (49-58)</td>
<td>62 (58-67)</td>
</tr>
</tbody>
</table>

*All values are given as median (Interquartile range).

**Table 4: Change in CD4+ profile after ATT (n=54) *.

<table>
<thead>
<tr>
<th>Age</th>
<th>No. (n=54)</th>
<th>Median CD4+ before ATT (Cells/mm³)</th>
<th>Median CD4+ after 6 months of ATT (Cells/mm³)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-34</td>
<td>25</td>
<td>94 (56-130)</td>
<td>242 (174-296)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>35-44</td>
<td>21</td>
<td>122 (91-157)</td>
<td>235 (184-329)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&gt;45</td>
<td>8</td>
<td>115 (50-173.5)</td>
<td>280 (245.5-363.75)</td>
<td>0.043</td>
</tr>
<tr>
<td>TOTAL</td>
<td>54</td>
<td>107.5 (51.5-150.75)</td>
<td>246 (184-335.75)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Values are given as median (Interquartile range).
We studied the clinical profile of these patients and found that the commonest symptoms in descending order were fever, lymphadenopathy, weight loss and cough with expectoration. Fever has also been shown to be the commonest manifestation of DTB. Therefore, TB remains an important cause in any HIV positive patient presenting with fever.

Organ systems involved in the tubercular disease process were individually evaluated by clinical, histological and radiological methods and the lymphatic system was the most commonly involved, with 35 out of 54 patients (64.81%) being diagnosed to have DTB of the lymphatic system alone or in conjunction with other organ systems. In another study done by this author, the incidence of lymph node involvement was 47.03%. Lymphadenopathy has been a common examination finding in various other studies as well. A clinician should keep a high level of suspicion for DTB in an HIV positive individual if presenting with lymphadenopathy, hepatomegaly, cough or signs of meningitis or bone and joint pains. In severely immune-suppressed patients with pulmonary tuberculosis, chest radiographs may be normal 10% – 40% of the time; however, a variety of abnormalities including effusion, lymphadenopathy and nodular opacities are also seen. In our study we found noteworthy radiological findings in 50 patients (92.6%), which included consolidation, pleural effusion, parenchymal opacities and hilar lymphadenopathy on CECT.

Chest and hepatosplenomegaly, retroperitoneal lymphadenopathy with ascites on abdominal ultrasonography.

An important finding of our study is that only 2 patients out of 54 (3.70%) were positive for Acid Fast Bacilli (AFB) on sputum examination while 52 remained sputum negative. This has a bearing on the diagnosis of DTB in a way that a majority of DTB and co-existing HIV positive patients would not provide positive sputum for AFB on Z-N staining, which is extensively used all across India. Similar results were shown by this author in another study, in which the incidence of smear negative TB was much more common than smear positive TB.

Histopathological examination of suspected tissues in the form of fine needle aspiration cytology (FNAC), biopsies and aspirates yielded a posi-
tive bacteriological diagnosis in 14 patients (25.93%), in whom a clinical or radiological diagnosis was in doubt. However, with advancing immune suppression, atypical findings including less well-formed granulomas maybe seen. Excisional biopsy has the highest sensitivity, whereas FNAC is less invasive and may be useful with a reduced sensitivity. The diagnostic accuracy could be further increased by combining the results of the biopsy histology, Polymerase Chain Reaction (PCR) and cultures. Likewise, both sensitivities (82.4%-100%) and specificities (94%-100%) were increased when fine needle aspiration (FNA) cytology and PCR were combined in the diagnosis of TB lymphadenitis.

Immunological profile of the patients was evaluated based on CD4 counts, which is a reliable indicator of the immune status of an individual. A meta-analysis estimated a 1.43-fold (95% credible interval: 1.16–1.88) increase in TB incidence per 100 cells per mm³ decrease in CD4 cell count. In our study, the CD4 counts of the HIV positive patients ranged between 4 and 338 cells/mm³ (median 110 cells/mm³); 92.6% of the patients had CD4 counts of <200 cells/mm³ and 25.9% had a CD4 count of <50 cells/mm³, indicating that a significant number of patients had profound immunosuppression at the time of investigation for symptomatic HIV/TB disease. In a South African study, it was seen that 61.2% had CD4 cell counts <200 cells/μL, 82.7% had counts <350 cells/μL. Patients were then put on a standard ATT regimen and CD4 levels were again checked at end of ATT. This showed a dramatic increase in all patients, with a median rise of 148 cells/mm³. With a CI of 95% and p value of < 0.001, this is a highly significant difference and supports the fact that a complete and early ATT institution can increase the CD4 count, thereby reducing the harmful effect of immunosuppression, as it is known that frequency and severity of DTB increases as CD4 counts fall. In an African study it was seen that CD4 cell levels increased significantly during the course of ATT in both HIV+ and HIV-TB-patients, but did not reach the levels in healthy subjects. In the same study it was shown that the continuous increase of CD4 cell counts during treatment for TB strongly suggests that TB per se contributes to subnormal CD4 cell levels in peripheral blood. Another study compared the improvement in CD4 count following ATT and ART initiation in patients presenting with HIV/TB dual infection with CD4 matched cohort of TB uninfected HIV patients initiated on ART and they found that in dually infected subjects, CD4 count improved from 150 cells/mm³ to 345 cells/mm³ (p = 0.001) and in the control TB uninfected patients, the change was from 159 cells/mm³ to 317 cells/mm³ (p = 0.001). This study showed that a greater increment in CD4 counts with ATT and ART in dually infected patients suggests that TB additionally influences the reduction of CD4 counts in HIV patients.

TB and HIV infection are wasting diseases that frequently occur together. Weight of the patients was assessed and recorded before and after ATT. On comparison, with a CI of 95% and p value <0.001, mean weight gain seen in patients after completion of ATT was seen to be 8.491 ± 5.436 kg, which is statistically significant. Maximum weight gain was seen in the fifth and sixth decades. In a study done in HIV negative patients it was seen that Indian patients with MDR-TB treated with individualized therapy reported that weight gain after 6 months of therapy was a predictor of successful outcome. Thus, it is evident that early and complete ATT helps in control of symptoms and improves the overall health status of an already immunocompromised individual. This subsidence of symptoms and monitoring of weight can go a long way in helping clinicians to monitor disease progress and institute appropriate interventions in case of unresponsiveness or failure of treatment as witnessed by worsening of symptoms or ongoing weight loss.

Another interesting finding of our study was that patient showed a significant fall in plasma viral load at the end of completion of ATT, the results of which were statistically significant. One of the possible explanations for this could be because of better adherence of ART which gets reinforced when patient develops a symptomatic opportunistic infection. Another big step by the government has been the integration of DOTS and National AIDS Control Programme (NACO) which helps in better co-ordination of the ART and ATT services which could help to improve the adherence to therapy. Various studies have shown increased HIV replication near site of tubercular granuloma which is dependent on the inflammatory milieu of the site. The successful control of TB infection could help limiting the viral replication, the results of which have been seen in our study. In a systemic review done to find out the effect of treatment of co-infections in HIV positive patients, it was seen that treatment of co-infections results in suppression of HIV plasma viral load. ATT has been shown to have various adverse effects on the body. In our study we found that only two patients of our study sample (3.7%) developed adverse reactions to ATT. Various other studies have shown the incidence of hepatotoxicity ranging from 6.9% - 8.7%.  

CONCLUSION

TB poses a significant threat to global health still today, causing the second highest mortality rates from an infectious disease worldwide, after HIV/AIDS. In this study, an analysis of 54 patients was done who were diagnosed to have Disseminated TB and HIV co-infection. Maximum cases were in the third decade of age. Radiological findings contributed to the diagnosis in 92.6% of the cases, 88.89% had clinical features suggestive of the disease but only 3.4% had sputum positive for AFB. Lymphatic system was the most commonly involved organ in this series (64.81%). Thus, it would be prudent to focus on the clinical findings with support of radiological investigations to diagnose DTB in seropositive cases of HIV rather instead of an advanced battery of investigations and that CD4 count is a reliable indicator of therapeutic response in such cases.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ABBREVIATIONS


REFERENCES

Thakur et al.: Clinical Profile of Disseminated TB in HIV Patients


